At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
RAD001drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating RAD001 for Pancreatic Cancer. Completed, enrolled 33 participants across 3 sites.
Detailed Summary
The purpose of this research study is to investigate if RAD001 is an effective treatment for pancreatic cancer that has spread and not responded to treatment. Experiments have shown that RAD001 can prevent cells from multiplying. RAD002 has also been tested in laboratory experiments imitating cancer conditions and the results have been promising.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2006
Enrollment StartJan 2007
Primary CompletionJan 2009
Study CompletionMay 2009
TodayJul 2026
First PostedDec 8, 2006
Enrollment StartJan 1, 2007
Primary CompletionJan 1, 2009
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 19.6 years ago
Interventions
RAD001drug
Taken orally daily for as long as the participant continues to receive a benefit.